AML: data to look forward to in 2018 and beyond

AML: data to look forward to in 2018 and beyond

VJHemOnc

1 year
185 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, gives his forecast of the acute myeloid leukemia (AML) data to look forward to in 2018 and beyond. Dr Stone highlights key data due to be release in 2018 for the trials of the second-generation FLT3 inhibitors quizartinib and gilteritinib vs. standard chemotherapy in advanced FLT3-mutated AML. He also anticipates the results of several significant venetoclax trials for AML. Furthermore, he discusses the immunotherapies to look out for, including antibody-drug conjugates, BiTES and DARTs. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
2 Views
ash 1 hour
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
0 Views
ash 2 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
0 Views
ash 10 hours
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
Category: Multiple Myeloma
2 Views
ash 10 hours
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
Category: Multiple Myeloma
2 Views
ash 10 hours
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
Category: Immunotherapy
0 Views
Cancer-News 11 hours
How Sensitive is the Technology? @PennMedicine @sellmyerlab
How Sensitive is the Technology? @PennMedicine @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
4 Views
iCMLf 1 day
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day